4AXM
 
 | | TRIAZINE CATHEPSIN INHIBITOR COMPLEX | | Descriptor: | 4-[(4-chlorobenzyl)(cyclohexyl)amino]-6-morpholin-4-yl-1,3,5-triazine-2-carboxamide, CATHEPSIN L1, GLYCEROL | | Authors: | Ehmke, V, Diederich, F, Banner, D.W, Benz, J. | | Deposit date: | 2012-06-13 | | Release date: | 2013-05-08 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Optimization of Triazine Nitriles as Rhodesain Inhibitors: Structure-Activity Relationships, Bioisosteric Imidazopyridine Nitriles, and X-Ray Crystal Structure Analysis with Human Cathepsin L
Chemmedchem, 8, 2013
|
|
4AXL
 | | HUMAN CATHEPSIN L APO FORM WITH ZN | | Descriptor: | ACETATE ION, CATHEPSIN L1, GLYCEROL, ... | | Authors: | Banner, D.W, Benz, J. | | Deposit date: | 2012-06-13 | | Release date: | 2013-05-08 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.92 Å) | | Cite: | Optimization of Triazine Nitriles as Rhodesain Inhibitors: Structure-Activity Relationships, Bioisosteric Imidazopyridine Nitriles, and X-Ray Crystal Structure Analysis with Human Cathepsin L
Chemmedchem, 8, 2013
|
|
9BTP
 | | Structure of human SHOC2 in complex with a small molecule inhibitor (R)-5 | | Descriptor: | (2S)-{2-[(4-chloro[1,1'-biphenyl]-3-yl)methoxy]phenyl}[(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)amino]acetic acid, Leucine-rich repeat protein SHOC-2, POTASSIUM ION | | Authors: | Dhembi, A, Hauseman, Z.J, King, D. | | Deposit date: | 2024-05-15 | | Release date: | 2025-04-02 | | Last modified: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (2.37 Å) | | Cite: | Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Nature, 2025
|
|
9BTN
 | |
9BTM
 | | NRas 1-169 Q61R in Complex with Shoc2 80-582 | | Descriptor: | GTPase NRas, GUANOSINE-5'-TRIPHOSPHATE, Leucine-rich repeat protein SHOC-2, ... | | Authors: | Hauseman, Z.J, King, D, Viscomi, J, Fodor, M. | | Deposit date: | 2024-05-15 | | Release date: | 2025-04-02 | | Last modified: | 2025-05-21 | | Method: | X-RAY DIFFRACTION (2.73 Å) | | Cite: | Targeting the SHOC2-RAS interaction in RAS-mutant cancers.
Nature, 2025
|
|
